IPG Health’s Chief Medical Officer Sommer Bazuro and Chief Strategy Officer Julie Pilon sat down with IPG’s Jen Sain to discuss how the network is building on its long-standing commitment to advancing clinical equality through their latest offering, designed to help pharma and healthcare companies diversify their clinical trials.
Sommer notes that our multidisciplinary approach seeks to ensure equitable representation across all dimensions, including race, gender, age and other intersectional groups. After several years working to raise awareness of a lack of diversity in clinical trials through The Trial for Clinical Equality, Sommer said clients began asking us to help them diversify their trials.
“Many healthcare providers may not openly discuss clinical trials with all of their patients, certainly not with minoritized patients,” Sommer said. “And if they do, it may not be framed in a culturally competent way that would really facilitate the patient’s understanding.”
Julie explained that “InQ,” Inclusion Intelligence Quotient, our strategic framework, is foundational to the new offering. She said it is key to understanding the audiences that could benefit from being in clinical trials and uses data to understand how to motivate a broader and diverse audience to participate.
“At the end of the day we want people to see themselves in the that work we create,” Julie said.
